Planet 13 Divests California Dispensary, Closes Cultivation Facility
November 3, 2025
Borealis Opens State-of-the-Art Cultivation, Production Facility in Connecticut
November 3, 2025
[PRESS RELEASE] – NEW YORK and HERZLIYA, Israel, Nov. 3, 2025 – InterCure Ltd. announced it has entered into a definitive share purchase agreement and a collaboration agreement with Cannasoul R&D Ltd., a globally recognized pioneer in cannabis research and analytics.
The share purchase agreement provides InterCure with a 28% ownership position in Cannasoul on a fully diluted basis and an exclusive path to increase its holdings to 51% within two years, while the collaboration agreement formalizes a partnership in research, development and commercialization of evidence-based cannabis therapeutics.
Notably, the agreements come as the U.S. cannabis market stands at a historic potential inflection point, with the Trump administration reportedly exploring the rescheduling of cannabis from Schedule I to Schedule III – a transformative regulatory shift that could potentially unlock unprecedented opportunities for international cannabis companies such as InterCure.
As part of the agreements, Prof. Dedi Meiri, founder of Cannasoul and a globally recognized cannabis researcher at the Technion – Israel Institute of Technology, is expected to be appointed as the chairperson of InterCure’s Scientific Advisory Board to be established by the company’s board of directors. In this role, Meiri will assist in integrating Cannasoul’s advanced analytics and research capabilities into InterCure’s pharmaceutical platform, strengthening InterCure’s scientific leadership and accelerating the development of next-generation cannabis-based therapeutics.
“The agreements mark a significant step in InterCure’s global leadership strategy,” InterCure CEO Alex Rabinovitch said. “By combining Cannasoul’s established research capabilities with InterCure’s pharmaceutical-grade platform and under the scientific advisory of Prof. Meiri, we plan to accelerate the development of next-generation cannabis therapeutics, expand our international footprint, and drive long-term value for patients and shareholders alike.”
“Cannasoul’s mission has always been to translate cannabis science into meaningful therapies,” Meiri said. “Through the agreements and with the establishment of the Scientific Advisory Board, we believe that we now have the structure, resources and global reach to move discoveries from the lab to patients faster, with the scientific rigor and scale that meaningful innovation demands.”
The transaction remains subject to customary closing conditions and regulatory approvals.
